header logo image


Page 19«..10..18192021..3040..»

Archive for the ‘Personalized Medicine’ Category

Medical Bioinformatics Market shares and strategies of key players – BioSpace

Friday, August 28th, 2020

Bioinformatics involves the development and application of novel informatics techniques in the field of biology. It improves the methods of storing, organizing, retrieving and analyzing biological data. Major activity in bioinformatics is to develop software tools in order to generate useful biological knowledge database. In molecular biology, bioinformatics techniques such as signal processing allow extraction of useful results from large amount of raw data. In the field of genetics it helps in sequencing, annotating genomes and to observe mutations. Bioinformatics study acts a biological literature and developmental data bank for biology related data.

Read Report Overview - https://www.transparencymarketresearch.com/medical-bioinformatics-market.html

Similarly, biomedical informatics is an emerging discipline which defines the study of inventions and implementation of structures, algorithms to improve communication, understanding and managing the medical information. The National Center for Toxicological Research (NCTR) conducts research in bioinformatics and chemo informatics. The bioinformatics tools were created for analysis and integration of genomics, proteomics, metabolomics datasets and transcriptomics.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16382

The growth of global medical bioinformatics market is driven by increasing initiatives and funding, use of bioinformatics in drug discovery and biomarkers. The market is expected to offer opportunities with the introduction and adoption of upcoming technologies such as cloud computing and other sequencing technologies. The global medical bioinformatics market can be segmented by tools approved from Food and Drug Administration (FDA) or European Federation for Medical informatics (EFMI) for further research process.

Medical Bioinformatics market is based on the tools, application and end users.

Request for Analysis of COVID-19 Impact on Medical Bioinformatics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=16382

The global medical bioinformatics market can be segmented based on types of tools and the list of bioinformatics tools approved by FDA are as follows:

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=16382

The global medical bioinformatics market can be segmented by application as follows:

The global medical bioinformatics market can be segmented by end user as follows:

Medical bioinformatics market is segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Rest of World. North America leads the market followed by the European nations in terms of revenue. Globally, the medical bioinformatics market growth is expected to increase with the demand in development of generic drug development and mode of sequencing the genes in order to have prevalence from various diseases. In 2015, Department of Biomedical Informatics was inaugurated at Harvard Medical School. This was initiated in order to bring quantitative methods and technological development to biomedicine engineering research. According to Harvard Medical School, Department of Biomedical Informatics (DBMI) and research associates planned to break the wall of autism by detecting the disorder in newborns using the same standard of testing device used to check for hearing impairment. According to Food and Drug Administration, collaboration with National Center for Toxicological Research has driven the demand and use of bioinformatics tools such as predicting patient-specific treatment outcomes with in silico tools. Latin America and Asia Pacific regions are anticipated to be the emerging markets in the global medical bioinformatics market during the forecast period. The effective guidelines from EFMI reports the promotion of high standard application and development in medical bioinformatics. Increase in patient population base and rising disease incidences in the Asia Pacific region is expected to fuel the use of bioinformatics tools for research and tests, which is projected to propel the demand in global medical bioinformatics market in the forecast period.

Pre Book Medical Bioinformatics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=16382&ltype=S

The key players in the global medical bioinformatics market develop bioinformatics tools, and software which is used in drug designing, sequencing methods. Some of the top players in the global medical bioinformatics market are Optra HEALTH, Affymetrix, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Paraxel, Station X and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse More Trending Reports by Transparency Market Research:

Liposomal Doxorubicin Market: https://www.transparencymarketresearch.com/liposomal-doxorubicin-market.html

Local Anesthetic Therapeutics Market: https://www.transparencymarketresearch.com/local-anesthetic-therapeutics-market.html

Preclinical CRO Market: https://www.transparencymarketresearch.com/preclinical-cro-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

The rest is here:
Medical Bioinformatics Market shares and strategies of key players - BioSpace

Read More...

M2GEN Announces the Launch of its Oncology-Focused Bioinformatics Support Services – PRNewswire

Friday, August 28th, 2020

TAMPA, Fla., Aug. 25, 2020 /PRNewswire/ --M2GEN announced today the launch of its oncology-focused Bioinformatics Support Services. Leveraging the results and knowledge gained from the ORIEN Avatar Program, an extensive, unique and ever-growing oncology clinico-genomics dataset, the M2GEN Bioinformatics team provides bioinformatics support services adhering to best-in-class standards.

M2GEN offers the following bioinformatics services: Paired Tumor and Germline Whole Exome Sequencing (WES) analysis with Panel of Normals (PoN) filtering, Tumor-Only Whole Exome Sequencing (WES) analysis with Virtual Normal (VN) somatic mutation classification, and Tumor-Only RNA Sequencing (RNA-Seq) analysis. Pipeline analysis is WES and RNA-Seq capture kit agnostic, and uses the most up to date human genome reference (GRCh38/hg38) and gene build (Gencode V32). All bioinformatics services are performed in HIPAA compliant and HI Trust certified cloud solutions.

M2GEN Bioinformatics Support Services utilize one of the largest Panel of Normals (PoN) available for high-quality somatic mutation calling. Over 20,000 germline samples from cancer patients inform the segregation of somatic and germline variants, and identify recurrent sequencing artifacts. In addition, the Avatar germline sequencing data is leveraged as a Virtual Normal (VN) cohort during Tumor-Only analysis, allowing for superior somatic mutation classification when patients' matched normal biospecimens are unavailable.

M2GEN's Bioinformatics Support Services are led by an experienced team of bioinformatics and computational biology experts trained at world-renowned scientific institutions such as Baylor College of Medicine Human Genome Sequencing Center, Memorial Sloan Kettering Cancer Center, European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Sanger Institute and Columbia University.

"M2GEN now provides next generation sequencing analysis pipelines to customers in academia and biopharma industry. Our end-to-end bioinformatics solutions and pipelines are tuned for large-scale oncology multi-omics studies that allow our customers to dedicate more time to results interpretation and discovery," said Oliver Hampton PhD, Vice President of Bioinformatics & Biostatistics at M2GEN.

"M2GEN continues to expand its portfolio of data solutions, services, and technologies to be the best partner possible for its clients as we transform cancer care together and make precision medicine a reality," said Helge Bastian, PhD, President & CEO of M2GEN. "M2GEN's bioinformatics services enable researchers in academic and pharmaceutical research worldwide to gain the most meaningful molecular insights in oncology. These molecular insights will accelerate the development of novel and more effective patient specific therapies, turning cancer into a manageable condition, or better still a curable disease."

About M2GEN

M2GEN is an oncology-focused health informatics solutions company with the mission to help patients get access to the best treatments by leveraging clinical and molecular data to accelerate the discovery, development and delivery of tailored and more personalized therapies. M2GEN's approach is to transform cancer care through identifying the genome analysis of patient-derived tumor specimens, and translating new molecular insights combined with clinical insights into individual therapeutics and / or diagnostic tools. For more information, visitM2GEN.com.

SOURCE M2GEN

m2gen.com

Read more:
M2GEN Announces the Launch of its Oncology-Focused Bioinformatics Support Services - PRNewswire

Read More...

Whole Exome Sequencing Market Industry Size, Growth, Analysis and Forecast to 2026 Eurofins Scientific Group, F. Hoffmann-La Roche AG, Bio-Rad…

Friday, August 28th, 2020

The global report on Whole Exome Sequencing market presents, through a comprehensive analysis, the newly published research study that provides key industry insights and a competitive advantage for multiple stakeholders. Whole Exome Sequencing report shows existing business research, future as well as emerging prospects, sales growth, potential investment, market size, pricing and profitability.

Major Players Covered in this Report are:Eurofins Scientific Group, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Beijing Genomics Institute, Pacific Biosciences of California Inc., Ambry Genetics Corp., GENEWIZ Inc., Agilent Technologies Inc., Macrogen Inc., Illumina Inc.

Final Whole Exome Sequencing Report will add the analysis of the impact of COVID-19 on this industry.

Request a Sample Copy to Understand the Impact of COVID-19 on Whole Exome Sequencing [emailprotected] https://www.marketgrowthinsight.com/sample/134935

The research on the Global Whole Exome Sequencing market 2020 offers a basic overview of the industry including concepts, classifications, applications and the structure of the supply chain. The Global Whole Exome Sequencing Market Report is given for global markets as well as trends in growth, competitive landscape analysis and the development status of key regions. Whole Exome Sequencing industry Development policies and plans will be discussed as well as processes of manufacturing and cost structures will also be analysed. In addition, Whole Exome Sequencing report includes import/export usage, supply and demand Statistics, expense, price, revenue and gross margins.

Geographically, the detailed analysis of consumption, revenue, Whole Exome Sequencing market share and growth rate, historic and forecast (2015-2026) of the following regions are covered:

North America (United States, Canada, Mexico)Europe (Germany, UK, France, Italy, Spain, Russia, Others)Asia-Pacific (China, Australia,South Korea,Japan, India, Southeast Asia, Others)Middle East and Africa (UAE, Saudi Arabia, Egypt, South Africa, Nigeria, Others)South America (Brazil, Argentina, Columbia, Chile, Others)

To get Incredible Discounts on this Premium [emailprotected] https://www.marketgrowthinsight.com/discount/134935

The Global Whole Exome Sequencing Market Report establish a range of primary and secondary research techniques to collect both quantitative and qualitative data on global and regional heads. Using different Whole Exome Sequencing industry-best analytical techniques, the overwhelming quantity of business data thus obtained is filtered and narrowed down to the Whole Exome Sequencing information that matter most to businesses operating in the sector or planning to enter.

The Whole Exome Sequencing study projects practicability analysis, SWOT analysis, and various other information about the leading companies operating in the Global Whole Exome Sequencing Market provide a detailed systematic account of the competitive environment of the industry with the aid of thorough company profiles. However, Whole Exome Sequencing research examines the impact of current market success and future growth prospects for the industry.

In this study, the years considered to estimate the market size of Whole Exome Sequencing are as follows:

Whole Exome Sequencing research provides answers to the following key questions:

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.

Contact Us:

Direct Line:+1 3477675477 (US)Email:[emailprotected]Web:https://www.marketgrowthinsight.com

Read more:
Whole Exome Sequencing Market Industry Size, Growth, Analysis and Forecast to 2026 Eurofins Scientific Group, F. Hoffmann-La Roche AG, Bio-Rad...

Read More...

IoT news of the week for August 14, 2020 – Stacey on IoT

Saturday, August 15th, 2020

Honeywell is getting the collaborative spirit:Honeywell, which recently signed a partnership with SAP to help organizations understand the financial performance of their buildings, has signed onto another collaboration, this time with oil services giant Halliburton. The focus here is on both collaboration and bringing data from each companys software to build new products and services. This is where the internet of things can really start to create value, because no one company will have all of the data necessary to document a business process. Its worth paying attention to these deals, noting how well they actually progress and what customers adopt. That way we can track if customers are really buying into the promise of IoT and, in turn, delivering value as part of an ecosystem. (Seeking Alpha)

Were finallyready to talk about standards for consumer wearables for medical-grade use cases: Silicon Valley has rushed to deliver wellness products in the form of activity trackers, sleep trackers, connected blood pressure cuffs, and EKG devices that run on your smartphone. But for the most part, these arent sufficient for medical-grade use cases because the data they produce isnt standardized or consistently tested in peer-reviewed studies. With the rush toward the remote monitoring of patients and remotely conducted clinical trials, the medical device industry is calling for Silicon Valley to help corral the Wild West of Datathat has emerged. In this essay, the authors call for companies to sign on to use standard, clinically validated methodologies for data collecting and sharing so researchers can compare results from patients wearing Fitbits to those wearing Apple Watches. Because while its fine if proprietary algorithms are used for the consumer-facing apps, for clinical trials, there needs to be more transparency. (Stat)

COVID cuts smart home revenue estimates:ABI Research says that in 2020, smart home device spending will rise by 4% from the prior year, to $85 billion. However, the new figure represents a $14.1 billiondecline in predicted sales, since prior to the pandemic analysts expected spending to rise by 21%.This data actually surprised me because it suggests that COVID-19 has cut the adoption of smart home devices despite many of us spending far more time at home. Given that job losses and economic uncertainty make it hard to shell out $50 for a smart light bulb, and that expensive security cameras arent really necessary if you never leave home, I guess the data makes sense. But I also wonder how many people are, like me, tired of reading about privacy violations and devices that lose their functionality and/or have security flaws. (CE Pro)

Its a cardiologist in a box?A startup called Bodyport has raised $11.2 million for its connected scale, which is designed to measure health. The scale is part of an overall medical-grade service that links a patient to their cardiologist and helps both track heart data without the need for in-person visits to a clinic. Im assuming that because of the pandemic the company sees a chance to push its version of sensors and algorithms to the medical industry and the masses. But at this point Im a little burned out by the mess of products competing to provide health monitoring without a focus on creating data standards and new systems for helping doctors manage what will be a huge influx of data.(Bodyport)

This is a fun-sounding startup: Las Vegas-based Terbine is trying to create a real-world market for data. This is a concept Ive been excited about for more than a decade, but technical and logistical challenges seem to keep it forever on the sidelines. On the technical side, some of the challenges include trying to move large amounts of data and the speed at which some data becomes stale. For example, weather data may be relevant for a long time, but theres a lot of it, so transferring it to another party comes with storage and associated bandwidth costs (the data gravity problem). Also, certain data such as traffic light data is only good for a few seconds or minutes, so a market would have to be faster than current ad exchanges. On the logistical side, most companies believe that their data is the new oil and want to hoard it, despite not knowing what to do with it or realizing that it would be more valuable when combined with data from other firms. So Ill keep an eye on Terbine because, as I said, I love this idea. (IMC)

Apptricity releases a Bluetooth tracker that can go the distance: Apptricity has shown off a Bluetooth hub and tracker that can measure a location for 20 miles, far beyond the typical 30-to-100-foot range that Bluetooth radio waves can travel. The boost means that Apptricity Bluetooth devices can compete with SigFox, LoRa, and other Low-Power Wide-Area Networks for tracking devices across large corporate campuses and warehouse settings. (Apptricity)

Personalized medicine could be coming closer:One of the ideas celebrated by futurists is that AI and the IoT can help deliver medical interventions personalized for each individual. This requires pretty intrusive surveillance of your body, but if you could get a customized treatment for your cancer that killed the cancerous cells while minimizing any side effects, youd probably take it. Now UCLA Samueli School of Engineering and the Stanford School of Medicine have built a smartwatch that analyzes a persons sweat to detect trace amounts of medicine in their body. This would allow doctors to calculate the exact amount of a drug that would be effective for each patient possibly reducing both the side effects and cost of treatment. (Medgadget)

This is a deep dive into new ways of performing machine learning on time-series data: For those of yall who are familiar with convolutional neural networks, recurrent neural networksand other ways of training computers to extract meaning from data, this article talks about a new technique that combines different training models and is optimized for time-series data. They are called temporal convolutional networks or TCNs. This is relevant for IoT folks, because a lot of the data generated by sensors is time-series data, and more efficient ways to train algorithms to handle such data could benefit many IoT applications. This is a dense read, but worth it. (Medium)

SiFive just got a lot more money: SiFive, the company making it easier for designers to build RISC-V processors, has raised $61 million in Series E funding, bringing its total funding to about $190 million. The company is banking on a new open-source chip architecture calledRISC-V that competes with MIPS, x86, and the Arm architecture. RISC-V is gaining ground because it doesnt have the high licensing fees associated with some of the other options, and because designers can freely customize it for specific workloads. A few companies are using RISC-V chips to build chips for the IoT.(HPC Wire)

Related

Original post:
IoT news of the week for August 14, 2020 - Stacey on IoT

Read More...

Golden Helix, Inc. Claims Position on Acclaimed Inc. 5000 List of Fastest-Growing Private Companies for Second Year Running – PRNewswire

Saturday, August 15th, 2020

BOZEMAN, Mont., Aug. 12, 2020 /PRNewswire/ --Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing solutions for over two decades. Today, they have been included in the esteemed Inc. 5000 list of rapidly growing American companies. Out of the 6 million business in the United States, Golden Helix has been honored with a spot in the annual list for the 2nd consecutive year.

Being ranked in the top 5000 places, Golden Helix is among some of the fastest growing and highly respected companies in both size and revenue a testament to the company's focus on innovation, quality, and customer satisfaction.

"We are ecstatic to be named among the country's leading companies. Next-Generation Sequencing is here to stay, and we are very appreciative to be experiencing global adoption of our solution stack," said Dr. Andreas Scherer, President and CEO of Golden Helix. "Our industry-leading CNV analytics capabilities in conjunction with state-of-the-art clinical workflows to diagnose cancer and rare diseases have differentiated ourselves in the marketplace. On top of that, we provide secure and scalable enterprise deployment capabilities with our data warehouse solution."

Of the tens of thousands of companies that have applied over the years, only a fraction of them makes the list more than once. The recognition comes on the heels of Golden Helix also being recognized by Healthcare Tech Outlook on its list of Top 10 Genetic Diagnostics Companies of 2020.

"The whole team at Golden Helix would like to thank each of our customers and partners for helping us become one of the fastest-growing biotech firms in the country," said Dr. Scherer. "I also want to thank the entire team at Golden Helix for all the creativity and dedication over many years in a competitive marketplace. We're honored to receive this recognition among so many remarkable companies."

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.

Delaina HawkinsGolden Helix, Inc(406) 999-0176[emailprotected]

SOURCE Golden Helix Inc

http://www.goldenhelix.com

More here:
Golden Helix, Inc. Claims Position on Acclaimed Inc. 5000 List of Fastest-Growing Private Companies for Second Year Running - PRNewswire

Read More...

Personalized Medicine Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 – Bulletin Line

Saturday, August 15th, 2020

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Personalized Medicine Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Personalized Medicine Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Personalized Medicine market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of10.67% from 2019-2026 and reachUSD 217.90 Billion by 2026.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Personalized Medicine Market are:

Competitive Landscape of the Personalized Medicine Market:

The market for the Personalized Medicine industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Regional Analysis of Personalized Medicine Market:

A brief overview of the regional landscape:

From a geographical perspective, the Personalized Medicine Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Personalized Medicine Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Continue reading here:
Personalized Medicine Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

Read More...

Communities Nationwide Remain Laser-Focused on Helping Cancer Patients Who Can’t Wait For Pandemic to Go Away – PRNewswire

Saturday, August 15th, 2020

LLS announced today, Rich Pentz and Tina Swallow were awarded the prestigious titles, National Man of the Year and National Woman of the Year, and broke new local campaign records, raising $518,906 and $467,686 respectively. The campaign has helped LLS invest nearly$1.3 billion, ensuring that the organization continues to deliver its cancer curing mission and impact for patients, who need support now, more than ever.

The funds raised through Man & Woman of the Year are used for:

"Cancer will not wait for COVID-19 to go away. And cancer patients can't wait either," said Louis J. DeGennaro, Ph.D., LLS president and CEO. "With the grit and determination of LLS supporters and volunteers like our Man & Woman of the Year candidates, LLS maintains a very significant, impactful mission agenda. We will continue to forge ahead relentlessly to find cures and help blood cancer patients access the care they need."

Pentz, a senior director of institutional sales and relationship management at Principal Global Investors in Indianapolis, IN, spearheaded "Team Echo" after accepting his nomination in memory of his mother, Patricia, who lost her battle to acute myeloid leukemia six years ago. He leveraged social media and organizedinnovative fundraising tactics in lieu of his other event plans, which were canceled due to COVID-19. Pentz said he was "elated beyond words" to find out his campaign, which culminated on his mother's birthday, June 20, broke a new fundraising record for Indiana."It's not about winning the title, it's about the impact we're makingon the cancer landscape," said Pentz.

Swallow, a 21-year Navy veteran and services director at Cisco in Washington, D.C., led "Team Bridge to a Cure" and ran her campaign in honor of her oldest son, Beau, who survived stage 4 cancer. "I've made it my mission to never stop fighting for cancer cures," said Swallow. "Just like LLS, my mission has not changed, what has changed is the urgency for patients."

The National Man & Woman of the Year runners-up were Jesse Giordano of "Team Unity" of Opal Wealth Advisors in Long Island, NY, and Lauren Palmer of "Team Gold" in Charlotte, NC they raised $437,510 and $352,792, respectively. The National "All Star" winners were Brian Fuller of "Team Lexie's Legacy" in Atlanta, GA, and Allison Jockel of "Team AML All Stars" in Charlotte, NC. Collectively, they raised more than $542,192. Fuller broke a new national All Star fundraising record and ran his campaign in memory of Lexie Clayton, a former LLS staff member who passed away from cancer at 36 years old.

To learn more about Man & Woman of the Year, visitwww.mwoy.org.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against cancer. The LLS mission: cure leukemia, lymphoma, multiplemyeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit http://www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

For additional information visitlls.org/lls-newsnetwork. Follow us onFacebook,Twitter, andInstagram.

The LLS Children's Initiative: Cures and Care for Children with Cancer

TheLLS Children's Initiativeis a $100 million multi-year effort to take on children's cancer through every facet of LLS's mission: research, patient education and support and policy and advocacy. The LLS Children's Initiative includes: more pediatric research grants, a global precision medicine clinical trial, expanded free education and support services for children and families and driving policies and laws that break down barriers to care. To learn more, visitwww.lls.org/childrens-initiative.

Media Contact:Kristin Hoose[emailprotected](914) 821-8973

SOURCE The Leukemia & Lymphoma Society (LLS)

http://www.lls.org

See the original post here:
Communities Nationwide Remain Laser-Focused on Helping Cancer Patients Who Can't Wait For Pandemic to Go Away - PRNewswire

Read More...

Impact Of Covid-19 on Cancer/ Tumor Profiling Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – The Daily…

Saturday, August 15th, 2020

Overview of Cancer/ Tumor Profiling Market Report Helps In Providing Scope and Definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Cancer/ Tumor Profiling market focuses on encompassing major statistical evidence for the Cancer/ Tumor Profiling industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Cancer/ Tumor Profiling study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Cancer/ Tumor Profiling industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Cancer/ Tumor Profiling market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Cancer/ Tumor Profiling report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Cancer/ Tumor Profiling market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Cancer/ Tumor Profiling Market report @ https://hongchunresearch.com/request-a-sample/58977

Key players in the global Cancer/Tumor Profiling market covered in Chapter 4:Illumina Inc. (U.S.)HTG Molecular Diagnostic (U.S.)Genomic Health Inc. (U.S.)NeoGenomics Laboratories (U.S.)QIAGEN N.V. (Netherlands)

In Chapter 11 and 13.3, on the basis of types, the Cancer/Tumor Profiling market from 2015 to 2026 is primarily split into:Next-generation SequencingIn Situ HybridizationImmunohistochemistryQuantitative PCR

In Chapter 12 and 13.4, on the basis of applications, the Cancer/Tumor Profiling market from 2015 to 2026 covers:Personalized MedicineBiomarker DiscoveryDiagnosticsPrognostics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Cancer/ Tumor Profiling market study further highlights the segmentation of the Cancer/ Tumor Profiling industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Cancer/ Tumor Profiling report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Cancer/ Tumor Profiling market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Cancer/ Tumor Profiling market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Cancer/ Tumor Profiling industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Cancer/ Tumor Profiling Market Report with [emailprotected] https://hongchunresearch.com/report/cancer-tumor-profiling-market-2020-58977

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Cancer/Tumor Profiling Market

Chapter Four: Players Profiles

Chapter Five: Global Cancer/Tumor Profiling Market Analysis by Regions

Chapter Six: North America Cancer/Tumor Profiling Market Analysis by Countries

Chapter Seven: Europe Cancer/Tumor Profiling Market Analysis by Countries

Chapter Eight: Asia-Pacific Cancer/Tumor Profiling Market Analysis by Countries

Chapter Nine: Middle East and Africa Cancer/Tumor Profiling Market Analysis by Countries

Chapter Ten: South America Cancer/Tumor Profiling Market Analysis by Countries

Chapter Eleven: Global Cancer/Tumor Profiling Market Segment by Types

Chapter Twelve: Global Cancer/Tumor Profiling Market Segment by Applications12.1 Global Cancer/Tumor Profiling Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Cancer/Tumor Profiling Sales and Market Share by Applications (2015-2020)12.1.2 Global Cancer/Tumor Profiling Revenue and Market Share by Applications (2015-2020)12.2 Personalized Medicine Sales, Revenue and Growth Rate (2015-2020)12.3 Biomarker Discovery Sales, Revenue and Growth Rate (2015-2020)12.4 Diagnostics Sales, Revenue and Growth Rate (2015-2020)12.5 Prognostics Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Cancer/Tumor Profiling Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/58977

List of tablesList of Tables and FiguresTable Global Cancer/Tumor Profiling Market Size Growth Rate by Type (2020-2026)Figure Global Cancer/Tumor Profiling Market Share by Type in 2019 & 2026Figure Next-generation Sequencing FeaturesFigure In Situ Hybridization FeaturesFigure Immunohistochemistry FeaturesFigure Quantitative PCR FeaturesTable Global Cancer/Tumor Profiling Market Size Growth by Application (2020-2026)Figure Global Cancer/Tumor Profiling Market Share by Application in 2019 & 2026Figure Personalized Medicine DescriptionFigure Biomarker Discovery DescriptionFigure Diagnostics DescriptionFigure Prognostics DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Cancer/Tumor Profiling Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Cancer/Tumor Profiling Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Cancer/Tumor ProfilingFigure Production Process of Cancer/Tumor ProfilingFigure Manufacturing Cost Structure of Cancer/Tumor ProfilingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Illumina Inc. (U.S.) ProfileTable Illumina Inc. (U.S.) Production, Value, Price, Gross Margin 2015-2020Table HTG Molecular Diagnostic (U.S.) ProfileTable HTG Molecular Diagnostic (U.S.) Production, Value, Price, Gross Margin 2015-2020Table Genomic Health Inc. (U.S.) ProfileTable Genomic Health Inc. (U.S.) Production, Value, Price, Gross Margin 2015-2020Table NeoGenomics Laboratories (U.S.) ProfileTable NeoGenomics Laboratories (U.S.) Production, Value, Price, Gross Margin 2015-2020Table QIAGEN N.V. (Netherlands) ProfileTable QIAGEN N.V. (Netherlands) Production, Value, Price, Gross Margin 2015-2020Figure Global Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Global Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table Global Cancer/Tumor Profiling Sales by Regions (2015-2020)Table Global Cancer/Tumor Profiling Sales Market Share by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue ($) by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue Market Share by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue Market Share by Regions in 2015Table Global Cancer/Tumor Profiling Revenue Market Share by Regions in 2019Figure North America Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Europe Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure South America Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure North America Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table North America Cancer/Tumor Profiling Sales by Countries (2015-2020)Table North America Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure North America Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure North America Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table North America Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table North America Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure North America Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure North America Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure United States Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Canada Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Mexico Cancer/Tumor Profiling Sales and Growth (2015-2020)Figure Europe Cancer/Tumor Profiling Revenue ($) Growth (2015-2020)Table Europe Cancer/Tumor Profiling Sales by Countries (2015-2020)Table Europe Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure Europe Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure Europe Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table Europe Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table Europe Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure Europe Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure Europe Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure Germany Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure UK Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure France Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Italy Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Spain Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Russia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Sales by Countries (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table Asia-Pacific Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure China Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Japan Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure South Korea Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Australia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure India Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Southeast Asia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read more here:
Impact Of Covid-19 on Cancer/ Tumor Profiling Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

Read More...

New AI-Based Software Precisely Assesses Progression of Retinal Legions from Geographic Atrophy – AZoRobotics

Saturday, August 15th, 2020

Written by AZoRoboticsAug 14 2020

Researchers from the Eye Clinic of the University Hospital Bonn, Stanford University, and the University of Utah have developed an artificial intelligence (AI)-based software that enables the accurate evaluation of the progression of geographic atrophy (GA).

Geographic atrophy is a disease of the light-sensitive retina that occurs due to age-related macular degeneration (AMD).

This novel technique enables fully automated measurement of the main atrophic lesions with the help of data obtained from optical coherence tomography, which offers three-dimensional visualization of the retinas structure.

Moreover, the researchers can accurately identify the integrity of light-sensitive cells of the whole central retina, as well as detect progressive degenerative variations of what are called the photoreceptors beyond the main lesions.

The study results will be used to evaluate the effectiveness of new innovative therapeutic approaches. The study was published recently in the JAMA Ophthalmology journal.

Currently, there exists no viable treatment for geographic atrophy, which is one of the most common reasons for blindness in industrialized nations. The disease impairs the cells of the retina and destroys them.

The main lesions, regions of the degenerated retina, also called geographic atrophy, tend to expand with the progression of the disease and lead to blind spots in the visual field of the patient. A main difficulty faced in the case of assessment therapies is that the lesions tend to progress gradually, implying that a long follow-up period is required for intervention studies.

When evaluating therapeutic approaches, we have so far concentrated primarily on the main lesions of the disease. However, in addition to central visual field loss, patients also suffer from symptoms such as a reduced light sensitivity in the surrounding retina.

Dr Frank G. Holz, Professor and Director, Eye Clinic, University Hospital Bonn.

Dr Holz added, Preserving the microstructure of the retina outside the main lesions would therefore already be an important achievement, which could be used to verify the effectiveness of future therapeutic approaches.

Moreover, the researchers could demonstrate that the integrity of light-sensitive cells exterior to the geographic atrophy areas is a predictor of the future progression of the disease.

It may therefore be possible to slow down the progression of the main atrophic lesions by using therapeutic approaches that protect the surrounding light sensitive cells.

Monika Fleckenstein, Professor, Moran Eye Center, University of Utah

Prof. Fleckenstein is the initiator of the Bonn-based natural history study on geographic atrophy, based on which this study was performed.

Research in ophthalmology is increasingly data-driven. The fully automated, precise analysis of the finest, microstructural changes in optical coherence tomography data using AI represents an important step towards personalized medicine for patients with age-related macular degeneration.

Dr Maximilian Pfau, Study Lead Author, Eye Clinic, University Hospital Bonn

Dr Pfau, who is currently a fellow of the German Research Foundation (DFG) and postdoctoral fellow at Stanford University in the Department of Biomedical Data Science, added that It would also be useful to re-evaluate older treatment studies with the new methods in order to assess possible effects on photoreceptor integrity.

Pfau, M., et al. (2020) Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. JAMA Ophthalmology. doi.org/10.1001/jamaophthalmol.2020.2914.

Source: https://www.uni-bonn.de/en?set_language=en

Continue reading here:
New AI-Based Software Precisely Assesses Progression of Retinal Legions from Geographic Atrophy - AZoRobotics

Read More...

DNA Sequencing Industry Outlook 2020-2025 – Increasing Application in Clinical Diagnosis & Drug Discovery is Driving Growth -…

Saturday, August 15th, 2020

DUBLIN--(BUSINESS WIRE)--The "Global DNA Sequencing Market: Growth, Trends & Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The Global DNA Sequencing Market is expected to witness a CAGR of 18.9% during the forecast period.

Certain factors that are driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis & drug discovery, and growing investment in R&D.

The technological advancements in sequencing, from 2D sequencing in the 1970's to DNA sequencing, has come a long way. In the recent years, platforms, such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. After the introduction of NGS technologies in 2005, they have had an incredible influence on genomic research.

Next-generation sequencing, currently, has its application in the diagnosis of a variety of illnesses, such as cancer, hematological disorders, neurology, psychiatry, dysmorphology, vision and hearing impairment, cardiology, and pharmacogenomics. It is also used as a tool for noninvasive prenatal tests. NGS technologies have been used for standard sequencing applications, like genome sequencing and for novel applications that were previously unexplored by using Sanger sequencing.

Applications include whole genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses.

Key Market Trends

Next Generation Sequencing is Expected to Show Lucrative Growth Opportunity in the Platform Segment

Next Generation Sequencing can be of several types based on the technology. For example, the benefits offered by whole genome sequencing technique, such as ease of handling, affordability, and accuracy, are expected to boost their demand. Additionally, these tests are usually preferred by the market players as a single test, which is capable of providing information on multiple factors, such as virulence, serotype, and resistance.

FDA is applying NGS in innovative ways, which can help reduce foodborne illnesses and deaths. Isolation of pathogens from food or environmental samples may be compared to clinical isolates from patients. A reliable link between the two is made, which helps define the scope of a foodborne illness outbreak. Owing to such factors the concerned segment is expected to observe a steady growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

The North America dominated the global market studied, in 2018, owing to the increasing funding and support activities by the government and non-government entities, especially in the United States. By supporting genomics research, various government bodies, like NHGRI (National Human Genome Research Institute) have supported the work on sequencing of the human genome, and fund research on the genome's structure, function, and role in health and disease.

They also support studies on the ethical, legal, and social implications (ELSI) of genome research. The US National Human Genome Research Institute and the US National Academy of Medicine, organized 90 leaders in genomic medicine from the United States, and 25 other countries in Genomic Medicine Symposium in 2014, in order to identify opportunities for collaborations that promote the responsible practice of genomic medicine.

Competitive Landscape

The DNA Sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Inc., Merck KGaA, Pacific Biosciences of California, Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., among others, hold the substantial market share in the DNA Sequencing market.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rise in Technological Advancements in DNA Sequencing

4.2.2 Increasing Application in Clinical Diagnosis & Drug Discovery

4.2.3 Growing Investment in R&D

4.3 Market Restraints

4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals

4.3.2 Legal and Ethical Issues

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 Product Type

5.1.1 Instruments

5.1.2 Consumables (Kits, Reagents)

5.1.3 Others

5.2 Platform

5.2.1 Sanger

5.2.2 Next Generation Sequencing

5.2.3 qPCR

5.2.4 Others

5.3 Application

5.3.1 Diagnostics

5.3.2 Personalized Medicine

5.3.3 Others (Biomarkers, Forensics, Reproductive Health etc.)

5.4 End User

5.4.1 Hospitals and Healthcare Organizations

5.4.2 Academics and Research Institutions

5.4.3 Pharmaceutical and Biotechnology Companies

5.4.4 Others

5.5 Geography

5.5.1 North America

5.5.2 Europe

5.5.3 Asia Pacific

5.5.4 Middle East and Africa

5.5.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Agilent Technologies, Inc.

6.1.2 Bio-Rad Laboratories, Inc.

6.1.3 Danaher Corporation (Beckman Coulter, Inc.)

6.1.4 Eurofins Scientific

6.1.5 F. Hoffmann-La Roche

6.1.6 Illumina, Inc.

6.1.7 Merck KGaA

6.1.8 Pacific Biosciences of California, Inc.

6.1.9 PerkinElmer Inc.

6.1.10 Thermo Fisher Scientific, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/29pmu9

Read this article:
DNA Sequencing Industry Outlook 2020-2025 - Increasing Application in Clinical Diagnosis & Drug Discovery is Driving Growth -...

Read More...

Outlook on the Worldwide Biomarkers Industry to 2025 Scientect – Scientect

Saturday, August 15th, 2020

The Biomarkers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Our analysts monitoring the situation around the Globe explain that after COVID-19 crisis the market will generate remunerative prospects for producers. The goal of the report is to provide a further illustration of the current scenario, economic slowdown and effect of COVID-19 on the industry as a whole.

Biomarkers Market was valued at USD 36.3 Billion in 2018 and expected to reach USD 91.4 Billion by 2025 with a CAGR of 14.1% during the forecast period. Increasing prevalence of cancer and growing precision medicine market are amongst the pivotal factors anticipated to spur the growth of Biomarkers Market.

The global biomarkers market is witnessing a healthy growth trajectory attributed to the growing application of biomarkers in diagnostics, increasing funding for biomarkers research, as well as its rising usage in drug discovery. Biomarkers are biological molecules found in body fluids and tissues that help in crucial clinical decision making and diagnosing various health conditions of the patients. Since the molecules can analyze pharmacological responses and pathological indications, they can effectively assist in process of drug discovery and development.

The diagnostics industry has been witnessing a shift in trend from using conventional diagnostic tools towards using more advanced diagnostic methods that focus on producing accurate and consistent results during early stage of diseases. This has led to boost in demand for biomarkers which are minimally or non-invasive tools to detect diseases such as cancer at early stage. Moreover, growing usage of precision medicine should further boost the biomarkers market growth.

Apart from this, expediting growth in the healthcare IT industry and low costs of clinical trials in emerging countries has favored the entry of various new players in the market. A large chunk of funding is being invested in research and development for new product launches. For instance, in March 2018, Genomic Health, Inc. launched the Oncotype DX AR-V7 Nucleus Detect test. The AR-V7 protein is a prognostic and predictive biomarker. This test aids physicians in taking therapeutic decisions in patients suffering from metastatic castration-resistant prostate cancer (mCRPC) by accurately detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTCs).

Recent Developments In May 2019, Qiagen announced the immediate launch of its first companion diagnostics assay therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) post U.S. FDA regulatory approval as a companion diagnostic to assist in diagnosing breast cancer patients that would be eligible for treatment with newly approved therapy PIQRAY (alpelisib) developed and marketed by Novartis.

Key Players in Biomarkers Market Some of the major players operating in the Global Biomarkers Market include Siemens Healthineers, Medtronic, F. Hoffman LA Roche Ltd., Abbott Laboratories Nexus-DX, Qiagen N.V., PerkinElmer, Inc., Lifesign LLC., Merck & Co, Inc., Bio-Rad Laboratories, EKF Diagnostics Holdings plc, Singulex, Inc., Signosis, Inc, and BioSims Technologies among others.

Global Biomarkers market is segmented on the basis of product, type, application, and disease indication. The Global Biomarkers Market by product includes consumables, services, and software, while based on type the industry is segmented into safety, efficacy, and validation. By application market segmentation includes diagnostics, drug development, personalized medicine, and disease risk assessment. Biomarkers market by disease indication comprises of cancer, cardiovascular diseases, neurological diseases, immunological diseases, and others.

Increasing incidence of cancer and growing precision medicine market are some of the pivotal factors boosting the Biomarkers market growth. Increasing incidence of cancer is one of the pivotal factors which is set to drive the growth of Biomarkers Market. According to World Health Organization (WHO) statistics, various types of cancer accounted for more than 9.5 million deaths in 2018 worldwide. Cancer biomarkers are released by cancer causing tumors that can be detected in blood stream and other tissues, thus helping in early clinical evaluation and deciding the course of treatment.

Moreover, the World Health Assembly has passed the resolution in 2017 for Cancer Prevention and Control. This integrated approach (WHA70.12) has recommended the governments and WHO to speed up action plans specified in the Global Action Plan and 2030 UN Agenda for Sustainable Development to reduce premature mortality from cancer. This has led to a boost in demand for early cancer screening tests and procedures. Increasing focus of research institutes to develop such biomarkers is likely to spur the global Biomarkers Market growth.

Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Biomarkers Market.

Key Benefits for Biomarkers Market Reports Global market report covers in-depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape.

By Product:ConsumablesServicesSoftware

By Type: SafetyEfficacyValidation

By Application:DiagnosticsDrug DevelopmentPersonalized MedicineDisease Risk Assessment

By Disease Indication:CancerCardiovascular DiseasesNeurological DiseasesImmunological DiseasesOthers

By Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

North America grabbed the largest share in Biomarkers Market globally In 2018, North America accounted for the largest share in the global biomarkers market owing to increasing adoption of precision medicine and rising prevalence of cancer in the region. The largest share of the region is also attributed to the rise in number of cancer cases in the U.S. and launch of Precision Medicine Initiative (PMI) by the U.S. government in 2015. According to the National Cancer Institute statistics, more than 16.5 million cases of cancer were diagnosed in 2016 in the U.S, and this number is expected to reach to 19 million in 2024.

The increasing application of biomarkers in the field of precision medicine should also drive the market in this region. Identification of biomarkers is essential for the development of precision medicine. The U.S. precision medicine industry has been booming post the launch of Precision Medicine Initiative by the government in 2015. The initiative aimed at improving the treatment outcome by offering tailor made therapies to patients. This has spurred the development of novel treatments and drugs based on an individuals genetic profile and characteristics of tumor. The Asia Pacific Biomarkers market is set to showcase lucrative growth in the coming years due to vast patient pool, increasing awareness regarding early disease detection and rising healthcare expenditure in the emerging countries of India and China.

Biomarkers Market Key Players: Siemens Healthineers Medtronic F. Hoffman LA Roche Ltd. Abbott Laboratories Nexus-DX Qiagen N.V. PerkinElmer, Inc. Lifesign LLC. Merck & Co, Inc. Bio-Rad Laboratories EKF Diagnostics Holdings plc Others

This comprehensive report will provide: Enhance your strategic decision making Assist with your research, presentations and business plans Show which emerging market opportunities to focus on Increase your industry knowledge Keep you up-to-date with crucial market developments Allow you to develop informed growth strategies Build your technical insight Illustrate trends to exploit Strengthen your analysis of competitors Provide risk analysis, helping you avoid the pitfalls other companies could make Ultimately, help you to maximize profitability for your company.

Our Market Research Solution Provides You Answer to Below Mentioned Question: Which are the driving factors responsible for the growth of market? Which are the roadblock factors of this market? What are the new opportunities, by which market will grow in coming years? What are the trends of this market? Which are main factors responsible for new product launch? How big is the global & regional market in terms of revenue, sales and production? How far will the market grow in forecast period in terms of revenue, sales and production? Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? Which region has more opportunities?

Table of Content1 Study Coverage1.1 Biomarkers Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Biomarkers Market Size2.1.1 Global Biomarkers Revenue 2014-20252.1.2 Global Biomarkers Production 2014-20252.2 Biomarkers Growth Rate (CAGR) 2020-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio2.3.2 Key Biomarkers Manufacturers2.3.2.1 Biomarkers Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Biomarkers Product Offered2.3.2.3 Date of Manufacturers Enter into Biomarkers Market2.4 Key Trends for Biomarkers Markets & Products

3 Market Size by Manufacturers3.1 Biomarkers Production by Manufacturers3.1.1 Biomarkers Production by Manufacturers3.1.2 Biomarkers Production Market Share by Manufacturers3.2 Biomarkers Revenue by Manufacturers3.2.1 Biomarkers Revenue by Manufacturers (2014-2020)3.2.2 Biomarkers Revenue Share by Manufacturers (2014-2020)3.3 Biomarkers Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Biomarkers Production by Regions4.1 Global Biomarkers Production by Regions4.1.1 Global Biomarkers Production Market Share by Regions4.1.2 Global Biomarkers Revenue Market Share by Regions4.2 North America4.2.1 North America Biomarkers Production4.2.2 North America Biomarkers Revenue4.2.3 Key Players in North America4.2.4 North America Biomarkers Import & Export4.3 Europe4.3.1 Europe Biomarkers Production4.3.2 Europe Biomarkers Revenue4.3.3 Key Players in Europe4.3.4 Europe Biomarkers Import & Export4.4 China4.4.1 China Biomarkers Production4.4.2 China Biomarkers Revenue4.4.3 Key Players in China4.4.4 China Biomarkers Import & Export4.5 Japan4.5.1 Japan Biomarkers Production4.5.2 Japan Biomarkers Revenue4.5.3 Key Players in Japan4.5.4 Japan Biomarkers Import & Export

5 Biomarkers Consumption by Regions5.1 Global Biomarkers Consumption by Regions5.1.1 Global Biomarkers Consumption by Regions5.1.2 Global Biomarkers Consumption Market Share by Regions5.2 North America5.2.1 North America Biomarkers Consumption by Application5.2.2 North America Biomarkers Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Biomarkers Consumption by Application5.3.2 Europe Biomarkers Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Biomarkers Consumption by Application5.4.2 Asia Pacific Biomarkers Consumption by Regions5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Top Trending Reports:

https://www.marketwatch.com/press-release/tart-cherry-market-size-share-from-2020-to-2025-growth-forecast-analysis-by-manufacturers-type-and-application-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/global-gaming-hardware-market-2020-industry-analysis-by-share-trends-growth-factors-cagr-status-growth-opportunities-segmentation-and-forecast-2025-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/obsessive-compulsive-disorder-ocd-market-2020-growth-analysis-share-demand-types-top-key-players-and-forecast-to-2025-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/geocells-market-size-revenue-analysis-growth-opportunities-and-forecast-2025-strata-systems-inc-wrekin-products-ltd-armtec-infrastructure-inc-maccaferri-spa-ace-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/at-1150-cagr-biophotonics-market-size-to-surpass-usd-8908-billion-by-2025-forecast-by-applications-dynamics-development-status-and-outlook-2025-2020-08-13?tesla=y

Read the original here:
Outlook on the Worldwide Biomarkers Industry to 2025 Scientect - Scientect

Read More...

Healthcare Descriptive Analysis Industry 2020-2025: Financial Data Analytics Expected to Dominate Over the Forecast Period – ResearchAndMarkets.com -…

Saturday, August 15th, 2020

The "Healthcare Descriptive Analysis Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Increasing need to reduce healthcare expenditure, including cost associated with medical product flaws and hospital workflow inefficiencies, is anticipated to increase the usage of big data in the healthcare sector.

The digitalization of healthcare data is also one of the primary drivers of healthcare analytics. According to Intel, approximately more than 80% of the healthcare organizations in the U.S. have adopted Electronic Medical Records (EMR) systems. These systems collect a lot of data, which can be analyzed using various types of healthcare analytics to develop personalized medicine.

Advanced methods such as predictive analytics are widely used in government organizations such as healthcare financing systems primarily to avoid frauds in payments. For instance, in 2011, the Centers of Medicare and Medicaid Services (CMS) reported that under its Fraud Prevention System (FPS), predictive analytics helped in saving USD 1.5 billion through improper payments. Moreover, the CMS is developing next generation predictive analytics, which is expected to boost the usage of predictive analytics.

Key Market Trends

Financial Data Analytics Segment Expected to Dominate the Market Over the Forecast Years

By application, the market has been segmented into clinical, financial, administrative, and research data analytics. The Financial Data Analytics segment is expected to register significant growth during the forecast period due to the technologically advanced solutions by healthcare providers and increased focus of payers on the early detection of fraud and reducing preventable costs.

North America Expected to Dominate the World Market

North America is expected to dominate the market followed by Europe. Factors, such as growing federal healthcare mandates to curb rising healthcare costs and provide quality care; increasing regulatory requirements; growing EHR adoption; and rising government initiatives focusing on personalized medicine, population health management, and value-based reimbursements are expected to drive market growth in North America.

Competitive Landscape

The Healthcare Descriptive Analysis market is moderately competitive and many of the global players are into the market. For instance - IBM, Inovalon, Cerner Corporation, Oracle Corporation, McKesson Corporation, MedeAnalytics, Inc., Optum, Inc., Allscripts Healthcare Solutions, Inc., etc. are providing healthcare descriptive analysis products across the globe.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Need for Comprehensive Analytics

4.2.2 Integration of Big Data into Healthcare

4.3 Market Restraints

4.3.1 Data Privacy and Security Concerns

4.3.2 High Costs of Initial Investment

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Application

5.1.1 Clinical Data Analytics

5.1.2 Financial Data Analytics

5.1.3 Administrative Data Analytics

5.1.4 Research Data Analytics

5.2 By Component

5.2.1 Software

5.2.2 Hardware

5.2.3 Services

5.3 By Deployment

5.3.1 On-Premise

5.3.2 Web-based

5.3.3 Cloud based

5.4 By End-user

5.4.1 Private organization

5.4.1.1 Hospitals

5.4.1.2 Physicians

5.4.1.3 Clinics

5.4.1.4 Others

5.5 Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 UK

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 Japan

5.5.3.3 India

5.5.3.4 Australia

5.5.3.5 South Korea

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle-East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle-East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 IBM

6.1.2 Allscripts Healthcare Solutions, Inc.

6.1.3 Cerner Corporation

6.1.4 Inovalon

6.1.5 McKesson Corporation

6.1.6 MedeAnalytics, Inc.

6.1.7 Optum

6.1.8 Oracle Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/iflgkx

View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005670/en/

Go here to see the original:
Healthcare Descriptive Analysis Industry 2020-2025: Financial Data Analytics Expected to Dominate Over the Forecast Period - ResearchAndMarkets.com -...

Read More...

Global Genomics in Cancer Care Market Professional Research By Regions, Types and Analysis of Key Players- Research Forecasts to 2027 – Daily Research…

Sunday, July 12th, 2020

Genomics in Cancer Care Market Analysis report studies latest market trends, development aspects, market gains and market scenario during the forecast period.

Latest Report published by Reportspedia titled: Global Genomics in Cancer Care Market Analysis report studies latest market trends, Market Share, development aspects, market gains and market scenario during the Forecast period 2019-2027. This study gives a comprehensive and detailed analysis of current and future 5-6 years market analyzed data of major players demanding on global market. The report explores key statistics on the Genomics in Cancer Care market status of the global and united states major industry players in detail.

Get Full Sample Report Including The In-depth Details: @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-genomics-in-cancer-care-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58342#request_sample

The Major Players Operating In Genomics in Cancer Care Market:

GE HealthcareBio-Rad LaboratoriesRoche DiagnosticsSigma AldrichPerkin ElmerAffymetrixIllumina IncAgilent TechnologiesCancer Genetics IncQiagen

It gives an detailed overview of the market, current trends, future 6 YEAR roadmap, Market challenges, industry environment, and also describes the industry chain structure & opportunities in the current market. This report Provides in-depth analysis of the scope of current and future market including the major factors such as Revenue forecast, company share, competitive landscape, growth factors, and trends, SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the industry. In addition, this report introduces market competition status among the merchants and company outline, besides, market demand analysis and value chain features are covered in this report.

Note: Upto 30% Discount On 2020 Reserch Report

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/58342

Significant Features Of Genomics in Cancer Care Report: :

Continue..

Customization Avaliable

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/life-sciences/2015-2027-global-genomics-in-cancer-care-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58342#inquiry_before_buying

Global Genomics in Cancer Care Market Split By Product Type And Applications :

By Type:

InstrumentsConsumablesServices

By Application:

DiagnosticsPersonalized MedicineDrug DiscoveryDevelopmentResearch

Genomics in Cancer Care Market Report Scope:

Table of Contents

Global Genomics in Cancer Care Market Research Report 2020 2027

For more Information or Browse the complete report @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-genomics-in-cancer-care-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58342#table_of_contents

Read the rest here:
Global Genomics in Cancer Care Market Professional Research By Regions, Types and Analysis of Key Players- Research Forecasts to 2027 - Daily Research...

Read More...

Personalized Medicine Market Size By Types, By Application, By Region, And Forecast 20202027 – Owned

Sunday, July 12th, 2020

New Jersey, United States,- The Personalized Medicine Market report upholds the future market predictions related to Personalized Medicine market size, revenue, production, Consumption, gross margin, and other substantial factors. It also examines the role of the prominent Personalized Medicine market players involved in the industry including their corporate overview. While emphasizing the key driving factors for the Personalized Medicine market, the report also offers a full study of the future trends and developments of the market.

The recently documented report on the Personalized Medicine market is a detailed analysis of this business landscape and contains important details regarding the present market trends, current revenue, market size, industry share, periodic deliverables, alongside the profit anticipation and growth rate registered during the estimated timeframe.

A thorough inference pertaining to the performance of the Personalized Medicine market over the forecast period, along with the key factors driving the market growth is enclosed in the report. It also delivers information about the market dynamics and focusses on the challenges encountered by the business vertical while providing a brief about the growth opportunities prevailing in the market over the analysis timeline.

Key highlights of the Personalized Medicine market report:

The essence of the regional bifurcation of the business sphere presented in the report:

Top key players of industry are covered in Personalized Medicine Market Research Report:

Personalized Medicine Market Classification by Types:

Bytype1

Personalized Medicine Market Size by End-user Application:

Byapplication1

Additional insights about the competitive landscape of the Personalized Medicine market:

Factors defining the competitive landscape included in the report are:

The Personalized Medicine market report encompasses a comprehensive analysis of the key facets including market concentration ratio.

The objective of the Personalized Medicine Market Report:

Cataloging the competitive terrain of the Personalized Medicine market:

Unveiling the geographical penetration of the Personalized Medicine market:

The report of the Personalized Medicine market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Personalized Medicine Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Personalized Medicine Market report

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Wireless EV Charging Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Personalized Medicine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Smart Robot Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

IOT in Elevators Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Narrowband IoT Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
Personalized Medicine Market Size By Types, By Application, By Region, And Forecast 20202027 - Owned

Read More...

Building on Strengths in Aging Care – The Lane Report

Sunday, July 12th, 2020

By Dianne H. Timmering

HEALTH CARE

COVID-19 has changed everything.

After any war, cities need to be rebuilt, national economies restored, global communities re-established. Due to the pandemic shutdown, Louisville Metro may face a $30-40 million deficit. And now after the recent public protests, that price tag may be even higher. The city has assets and aspirations, however.

Among those aspirations is Louisvilles goal to become the aging innovation capital of the world. The aging-care segment of health care is worth about $8 trillionmeaning that if Louisville captured even 1% of the market, it would represent some $80 billion annually for the city.

Some of that is already happening, but creating a collaborative economic ecosystem netting just 1% of aging care would mean a cash flow of more than a third of Kentuckys current gross domestic product (GDP), creating significant opportunity. A flourishing Louisville aging-care cluster could rebuild a strong economy by supplying the rapidly growing new demands and needs of an aging world.

As the source of more than 40% of Kentuckys tax revenues, Louisvilles economic importance to the state is already great. Yet, imagine what becoming a major aging innovation capital could be worth to a city in financial distress. A health care renaissance could resolve economic burdens that we havent seen since the Great Depression.

In times of crisis, you go to your strengths and we have that strength in health care aging innovation, said Mary Ellen Wiederwohl, chief of Louisville Forward. And while U.S. cities begin the recovery from both a health pandemic and a reckoning from institutional racism in this country, we need to think about how were going to build back our economy in a way that benefits all of our residents. By going to one of our core strengths, we have a greater opportunity to do so.

Anthony Ellis, the Kentucky Cabinet for Economic Developments acting executive director of KY Innovationthe agencys entrepreneurship officeunderscored the importance of Louisvilles efforts.

We are extremely excited about Louisvilles continued growth in the entrepreneurship and startup sector. With strong leadership in its support organizations like LHCC (Louisville Healthcare CEO Council) and the RISE office (a nonprofit that supports refugees and immigrants), a vibrant and active sector, and collaborative mentors, Louisville is primed for explosive growth as we head into this economic recovery. Aging care is a clear sector for our startup community to target, as Louisville and the commonwealth generally have a robust health care and long-term care industry, and have been a driving force in developments in these segments, said Ellis, who is also the Cabinets general counsel.

As a cabinet, we work to grow jobs, recruit talent and generate business investment in all 120 Kentucky counties. When our largest city and so many of its community leaders come together to collaborate on a project like this, its exciting for the commonwealth as a whole. We at the state are committed to this effort and supporting these innovation activities.

Gov. Andy Beshear is also behind Louisvilles initiative.

The pandemic and recent protests have created both urgency and opportunity in ensuring we build a more equitable future for all Kentuckians, including our older citizens. The partners working to grow Louisville as an aging-care hub are exactly who youd want on your team, Gov. Beshear said. We support the aging-care vision for Louisville and consider the commonwealth a committed partner. Whether in our recruiting, marketing, helping existing businesses grow or by partnering to create a strong startup and innovation culture, Team Kentucky is working toward that same future.

Health care has changed. Health care will change. Leaders of a health-care consortium in the city of bourbonism (a term the city has created to define the tourism draw of its many bourbon-related sites) and horses believe aging innovation can be the front-line of its future. They see it creating trends to solve and fill gaps, evolving solutions to needs and demands in a new health care world while also improving wellness and driving new care modelsif Louisville can create the framework to support innovation.

There are significant building blocks and cornerstones, some new, some having emerged over years:

The Microsoft Digital Alliance Partnership and Future Work Initiative in partnership with the city, the University of Louisville, and the Brookings Institution was created in 2019 to build a regional digital ground zero for artificial intelligence (AI) and the internet of things (IoT).

Much of the thrust is centered on digital transformation of the workforce for a tech future. It is no coincidence that Louisvillehome to multiple champions of aging health care, from insurance to post-acute care to hospiceattracted this partnership. Together, all the above could be a natural alignment to lead aging innovation.

We are grateful to Microsoft. They see an opportunity that has some unique advantages to be driving innovation in the data economy, which is connected to our aging cluster, said Ben Reno-Weber, director of the Microsoft Future of Work Initiative. Louisville, like no other city, has a reservoir of data resources that can trace data across an entire companys lifecycle. Theres not a place where you can do that everywhere.

Reno-Weber urges a reframing of how to see data. He imagines shifting its current view from that of a cost center into an integral part of doing business, especially with the aging silver tsunami now arriving.

Once we build that infrastructure, he said, because health care concentration is such an important part of our industry, success in the data economy is not about the technical shift but a cultural one. If a company in the health care space is going to be successful, it must change the way it sees data as a corporate asset.

The aggregated power of the Big 12 companies now known as the Louisville HealthCare CEO Council (LHCC):

Some key partnerships are evolving within the LHCC, whose companies (with $100 billion in revenue) represent the length, breadth and complexities of the health care ecosystem, from payor to provider to those on the front lines of solving health care problems. Those initial discovery labs will likely evolve now based on the new normal, such as the need for elevated infection control, the emergence of telemedicine, and a first line of defense against a second COVID-19 wave.

Post-COVID aging innovation solutions will center around the need for intense infection control, says Dr. Arif Nazir, immediate past president of The Society for Post-Acute and Long-Term Care Medicine and chief medical officer at Signature Healthcare, a LHCC member.

We all need to be better stewards of infection control patterns, Nazir said. Just think about whats possible here with new competencies in infection control like face recognition and the ability to trace ones steps and who used the sink last, how long hands were washed.

With one in five Americans soon to be 65 or older, LHCC is stepping into the leadership limelight in aging innovation with its upcoming Global Healthcare Summit, now scheduled for Sept. 2-3, 2020. One of the goals of the summit is for national and world leaders and communities to take note: Louisville is solving global problems and community health issues.

International pharma is focusing on Louisville and the power of real data-sharing. Pfizer Inc. and the University of Louisvilles Division of Infectious Diseases have an established history of collaboration. Their synergistic alliance now will become the basis for one of the first of eight adult population research centers being placed globallyand the only one in North America. UofL will play a significant role in epidemiological research related to vaccine-preventable diseases affecting adults, including the elderly, a recent UofL news release states.

The reason for the selection, Reno-Weber said, is that nine hospitals that treat in Louisville are willing to share their data. At least one of the senior physicians was trained at CERID (The Center of Excellence for Research in Infectious Diseases).

Aging2.0 partnership and relocation to the city:

Anticipating the next chapter for boomers, Aging2.0 was founded in 2012 on the West Coast to address the need for aging innovation with a public-private approach and international reach that has grown to 40,000 innovators across 31 countries, with a chapter network that spans 120 cities and 700 events around the world.

Aging2.0 moved its headquarters to Louisville in May, announcing a strategic alliance with LHCC that enhances the citys recognition as a global epicenter.

Ecosystem emerged from Humana

The citys culturally rich aging-care hegemony has its roots in Humanas early history in the 1960s, when it became the largest nursing home company in the U.S., then transformed into one of the largest hospital companies, and next launched its own health insurance plan in the 1980s. As the American health care system changed, so did Humana. The companys alumni spun proficiencies they developed there into new companies that today are an ecosystem.

When an industry has thus chosen a locality for itself, the great 19th-centuryeconomist Alfred Marshall wrote, it is likely to stay there long, so great are the advantages which people following the same skilled trade get from near neighborhood to one another. The mysteries of the trade become no mysteries; but are as it were in the air, and children learn many of them unconsciously.

Louisville might next evolve into a driver of expertise in staffing advancements; cures; the tech embrace of data realities; precision medicine; virtual care; the social determinants of outcomes; and the power of the one-on-one to deliver personalized health care that has never existed before.

LHCC members want real data share opportunity that can link with and push statewide advances out through the university system. They imagine Louisville being the pandemic crusader and COVID-19 killer for the worldespecially as the leader in aging innovation, saving the most vulnerable among us.

Its that cultural piece that is potentially powerful, Reno-Weber said. Either we take advantage of it or we dont.

Louisville still needs money and trust

The finances of funding startup innovation and sustaining those start-ups through pivots and evolution to achieve sustainability are complex.

Entrepreneurs do, indeed, raise real money locally. In 2019, $70 million in capital was invested in Louisville. Investors often want the company to remain local for obvious reasons: community investment, access to the build, future growth implications, proximity to health care or pilot companies. They want companies to access ongoing local support and the navigational advantages of newer organizations like Louisville Entrepreneurship Acceleration Partnership (LEAP), and stalwarts like XLerate Health. There is growing a sense that having the money in Louisville and keeping it here is not the disadvantage that it may have once been.

But those involved in the Kentucky funding community have long said there still is not enough of it. There are, indeed, a lot of angel and venture groups out there and a robust smaller investment category for super start-ups for $1 million or less, says Gill Holland, a community leader and developer who launched reinvigoration of the NuLu area just east of downtown. What were lacking is the $1 to $5 million for a $10 million raise. We need to get better at attracting out-of-town money.

One local innovator, for example, received an investment from a Columbus, Ohio, incubator but then had to move his company there. And other startups dont need large amounts of money, Holland said, because theyre more centered around the ones and zeros of computer programming.

What Louisville lacks and does need if it is to attract and encourage creative entrepreneurshipespecially when solving for the aging care and innovation gapsare the bigger dollars of serious equity investment and the funding that can take a solution to manufacturing and be able to see it through an FDA approval process, Holland said.

Such a robust investment community could support, for example, an innovator like Crestwood, Ky.-based Liberate Medical, which is being recognized for its external electrical neuromuscular ventilator technology, which can speed patient liberation from mechanical ventilation. Due to the increased need for ventilators caused by the COVID-19 pandemic, the technology now has the sudden opportunity to be fast-tracked by the Food and Drug Administration (FDA).

Kelby Price, executive director of Venture Capital at Kentucky Science and Technology Corp., agrees.

Growing Series A investment activity will require more talent, more new companies or starts, and more successful exits, Price said. Simply said, in order to do it here, the source of the deal or local investors needs to be successful.

Instead, says Larry Horn, director of LEAP, there is a sucking sound from the venture capital community outside of the state, looking to take away companies with good ideas.

LHCC aims to reverse that financial draw by creating not just opportunity for aging care-based innovation but new capital dollars from pre-seed to Series B. In 2019 it launched the LHCC Strategic Investment Fund in partnership with an already-established investment committee. The funds goal is to deploy the type of dollars that can scale innovation and generate financial momentum and wider revitalization.

According to Horn, Louisville investors can protect their investment and its value by maintaining it right in the city where its being developed, grown and piloted. A lead advantage for Louisville, he argues, is that the communitys density of knowledge is offering more than just money but mentorship and inroads to potential customers.

Louisvilles health care industry offers comparative advantages to leverage early-stage companies faster: validating that a problem has a possible business solution, pilot-testing strategically with first customers, a willingness to assume the risk of trying new things, and the market in which to do it.

There are a lot of ingredients there, Price said.

Holding them together will require a culture of trust, which is necessary in order to believe that collaboration can create more value, not competition. Potential impediments to success could be inadequate trust among the Big 12 LHCC members on the data share; navigating 12 unique corporate cultures for early investment dollars; a well-developed pilot that never lifts off; or a stalled opportunity in early adoption phase due to compliance or other legal burdens in an over-regulated HIPAA nation.

Solving for the new normal

Now is the time for Louisville to take the lead in AI based solutions, LHCC member Nazir said, including the automation of wearables so when a doctor logs in, he or she already has 1,000 readings from the pulse rate and we can then start to see trends in their health.

By automating data gathering for significant health determinants, personalized health care evolves. It allows matching community resources with the background of the patient, enabling clinicians to offer better patient care and services.

With wearables, Nazir said, there are more eyes on his patientsdigital eyes that do not tire. And he can focus on responding to needs better and faster while being able to adapt care plans or pathways.

He and other LHCC members see a health care that could involve the following:

Wearablesa new kind of technology that fulfills the need for a better understanding on what is going on in the patients body. For instance, simple matters like how any times a patient is turned in a hospital bed can be significant. Human resources make it impossible for a one-on-one clinical patient ratio but with wearables and real-time data, might feed AI for a type of robotic nurse.

Personalized medicine through geneticsgiving the patient what they need via a personalized medicine, which links to the data-share opportunity between the Big 12 and the citys digital alliance with Microsoft. The COVID-19 experience is accelerating the arrival of a new landscape of digital medicine that the world is increasingly ready for.

Technology with a human touchTelemedicine and broader-based telehealth solutions are all the rage with their urgent adoption due to the dual needs of preventing transmission and getting care to elders who are the most vulnerable to the coronavirus. But it cannot replace the care given face-to-face. While doctors and clinicians are embracing it for many reasons, social distancing is still considered a temporary practice, and care delivery remains a very organic relationship.

Specialties will begin to expandTechnology is creating an opportunity to push more specialist care out into the system. The medical community already is curious after this springs telehealth regulatory waivers to see where health care licensing rules go, as well as interstate commerce of physicians and specialists across state lines.

Creativity in financial controlsPayors are embracing technology for prevention, compassion and lowered costs. Insurance is granting more flexibility of services. Rebranding American health care, with new codes, new waivers and new requests will become a necessity for driving quality care into rural areas, for preventing COVID-19 for patients and staff alike, and making distance care an option.

Filling the need for a new normal

The new normal almost forces a new philosophical framework overlay that has ruled this country since its foundational pillar of capitalism and individualism.

Deficits at the city, county and state levels will demand a new economy with new economic realities. Meeting budgetary shortfalls and bankruptcy threats may be solved by the density of health care knowledge right in the heart of Louisvilleif pooled into a post-COVID strategy to revitalize an economy that drives job growth, tax revenues and repopulates hope.

Greater Louisvilles health care leaders think they have the goods, the expertise, the brilliance, the industry respect, the global outreach and the existing infrastructure to figure this out. And a billion people need it.

Dianne H. Timmering is a correspondentfor The Lane Report. She can be reachedat [emailprotected]

Originally posted here:
Building on Strengths in Aging Care - The Lane Report

Read More...

‘MasterChef’s Resident KatyCat Reece Was Eliminated Tonight & Is Somebody Cutting Onions? – Pedestrian TV

Sunday, July 12th, 2020

Well folks, I guess we can just endMasterChefright here because sweet angel boyReece Hignellhas officially left the kitchen and to quoteMy Chemical Romance:Im not okay.

Maybe I had a soft spot for him as the shows token vegan and token KatyCat, but simply cannot stress how hard I was rooting for him.

But unfortunately, no matter how hard I try, I am notMelissa Leong and therefore, did not have the power to save our beloved Reece tonight.

Thankfully, he had a good run and even got to meet his idolKaty Perryat one point this season.

Tonights episode saw the remaining contestants battle it out presenting a four-course meal for some of the countrys greatest chefs.

Ultimately, it came down to Reece andCallum, who served up vegetables and dessert respectively.

But unfortunately for Reece, the judges felt like he didnt quite try hard enough, while Callum tried a little ~too~ hard.

When the decision was handed down, poor, sweet Reece was sent packing.

Fans were understandably heartbroken.

We simply cannot handle this.

Justice for our OG KatyCat.

Oh, and while were at it, give him a TV show too.

Seriously, Im sobbing. I cannot handle this.

I know, I know, every elimination when it gets down to the final few is tough. But GOD, I didnt expect it to be THIS emotional.

All of the MasterChef contestants are just so wholesome, at least when aBachiecontestant gets the boot theyve usually done something to warrant it. But all of these people are just trying to make tasty food! Cant they all win? Give them all a prize! Participation trophies for all!

Visit link:
'MasterChef's Resident KatyCat Reece Was Eliminated Tonight & Is Somebody Cutting Onions? - Pedestrian TV

Read More...

Decoding the Future Trajectory of Healthcare with AI – Digital Market News

Sunday, July 12th, 2020

Artificial Intelligence (AI) is getting increasingly sophisticated everyday in its application, with enhanced efficiency and speed at a lower cost. Every single sector has been reaping advantages of AI recently. The Healthcare industry isnt any exception. Here is decoding the future trajectory of healthcare with AI.

- Advertisement -

The impact of artificial intelligence in the healthcare industry through machine learning (ML) and natural language processing (NLP) is transforming care delivery. Additionally, patients are expected to achieve relatively high access to their health-related information than before through various applications such as for instance smart wearable devices and mobile electronic medical records (EMR).

The personalized healthcare will authorize patients to just take the wheel of their well-being, facilitate high-end healthcare, and promote better patient-provider communication to underprivileged areas.

- Advertisement -

For instance, IBM Watson for Health is helping healthcare businesses to apply cognitive technology to supply a vast amount of power diagnosis and health-related information.

In addition, Googles DeepMind Health is collaborating with researchers, clinicians, and patients to be able to solve real-world healthcare issues. Additionally, the company has combined systems neuroscience with machine understanding how to develop strong general-purpose learning algorithms within neural networks to mimic the mind.

Companies are working towards developing AI technology to resolve several existing challenges, particularly within the healthcare space. Strong give attention to funding and starting AI healthcare programs played a substantial role in Microsoft Corporations decision to launch a 5-year, US$ 40 million program referred to as AI for Health in January 2019.

The Microsoft program will use artificial intelligence tools to resolve some of the greatest healthcare challenges including global health crises, treatment, and infection diagnosis. Microsoft has also ensured that academia, non-profit, and research businesses have access to this technology, technical experts, and resources to leverage AI for care delivery and research.

In January 2020, these factors influenced Takeda Pharmaceuticals Company and MITs School of Engineering to join hands for 36 months to drive innovation and application of AI in the healthcare industry and drug development.

AI applications are just centered on three main investment areas: Diagnostics, Engagement, and Digitization. With the rapid advancement in technologies. There are exciting breakthroughs in incorporating AI in medical services.

The most interesting aspect of AI is robots. Robots arent only replacing trained medical staff but in addition making them more efficient in a number of areas. Robots help in controlling the cost while potentially providing better care and performing accurate surgery in limited space.

China and the U.S. have started investing in the development of robots to guide doctors. In November 2017, a robot in China passed a medical licensing exam only using an AI brain. Also, it was the first-ever semi-automated operating robot that was used to suture blood vessels as fine as 0.03 mm.

In order to avoid coronavirus from spreading, the American medical practioners are counting on a robot that can measure the patients act and vitals. In addition, robots are also used for recovery and consulting assistance and transporting units. These robots are showcasing significant potential in revolutionizing medical procedures in the future.

Precision medicine is an emerging approach to infection prevention and treatment. The precision medication approach allows researchers and doctors to predict more accurate treatment and prevention strategies.

The advent of precision medicine technology has allowed healthcare to actively track patients physiology in real-time, take multi-dimensional data, and create predictive algorithms that use collective learnings to calculate individual outcomes.

In modern times, there has been an immense give attention to enabling direct-to-consumer genomics. Now, companies are aiming to create patient-centric products and services within digitization processes and genomics linked to ordering complex testing in clinics.

In January 2020, ixLayer, a start-up based in San-Francisco, launched one of its kind precision health testing platforms to improve the delivery of diagnostic testing also to shorten the complex relationship among physicians, precision health tests, and patients.

Personal health monitoring is really a promising example of AI in healthcare. With the emergence of advanced AI and Internet of Medical Things (IoMT), demand for consumer-oriented products and services such as smart wearables for monitoring wellbeing is growing notably.

Owing to the rapid proliferation of smart wearables and mobile apps, enterprises are introducing varied options to monitor personal health.

In October 2019, Gali Health, a health technology company, introduced its Gali AI-powered personal health assistant for people struggling with inflammatory bowel diseases (IBD). It offers health tracking and analytical tools, medically-vetted educational resources, and emotional support to the IBD community.

Similarly, start-ups are also coming forward with innovative devices integrated with state-of-the-art AI technology to contribute to the growing demand for personal health monitoring.

In modern times, AI has been found in numerous methods to support the medical imaging of all types. At present, the biggest use for AI would be to assist in the analysis of images and perform single narrow recognition tasks.

In the United States, AI is known as highly valuable in enhancing business operations and patients care. It has the greatest affect patient care by improving the accuracy of clinical outcomes and medical diagnosis.

Strong presence of leading market players in the country is bolstering the demand for medical imaging in hospitals and research centers.

In January 2020, Hitachi Healthcare Americas announced to start a brand new dedicated R&D center in North America. Medical imaging will leverage the advancements in machine learning and artificial intelligence to result in next-gen of medical imaging technology.

With plenty of dilemmas driven by the growing rate of chronic infection and the aging populace, the requirement for new innovative solutions in the healthcare industry is moving on an upswing.

Unleashing AIs complete potential in the healthcare industry is not a facile task. Both healthcare providers and AI developers together must tackle all the obstacles on the path towards the integration of new technologies.

Clearing all the hurdles will need a compounding of technological refinement and shifting mindsets. As AI trend become more deep-rooted, it is giving rise to highly ubiquitous discussions. Will AI replace the health practitioners and medical experts, especially radiologists and physicians? The reply to this is, itll increase the efficiency of the medical experts.

Initiatives by IBM Watson and Googles DeepMind will soon unlock the critical answers. However, AI aims to mimic the mind in healthcare, human judgment, and intuitions that cant be substituted.

Even though AI is augmenting in existing capabilities of the industry, it really is unlikely to completely replace human intervention. AI skilled forces will swap only people who dont wish to embrace technology.

Healthcare is a dynamic industry with significant opportunities. However, uncertainty, cost concerns, and complexity are rendering it an unnerving one.

The most useful opportunity for healthcare in the near future are hybrid models, where clinicians and physicians will be supported for treatment planning, diagnosis, and pinpointing risk facets. Also, with an increase in the number of geriatric population and the rise of health-related concerns across the globe, the over all burden of disease management has augmented.

Patients are also expecting better treatment and care. Due to growing innovations in the healthcare industry with respect to improved diagnosis and treatment, AI has gained consideration among the patients and health practitioners.

In order to develop better medical technology, entrepreneurs, healthcare service providers, investors, policy developers, and patients are coming together.

These facets are set to exhibit a brighter future of AI in the healthcare industry. It is very likely that there will be widespread use and massive advancements of AI integrated technology in the next several years. Moreover, healthcare providers are anticipated to invest in sufficient IT infrastructure solutions and data centers to support new technological development.

Healthcare companies should continually integrate new technologies to build strong value also to keep the patients attention.

-

The insights presented in the article are derived from a recent study on Global Artificial Intelligence In Healthcare Market by Future Market Insights.

Abhishek Budholiya is really a tech blogger, digital marketing pro, and contains contributed to varied tech magazines. Currently, as a technology and digital branding consultant, he offers his analysis on the tech general market trends landscape. His forte is analysing the commercial viability of a brand new breakthrough, a trait you can view in his writing. When he is maybe not ruminating about the tech world, he is able to be found playing ping pong or chilling out with his friends.

See the original post here:
Decoding the Future Trajectory of Healthcare with AI - Digital Market News

Read More...

Researcher leads international study of patients at risk of heart failure and death – UCalgary News

Saturday, July 11th, 2020

Heart failure impacts between three to four per cent of the general population. While commonly related to heart attacks it can also be due to a condition called dilated cardiomyopathy (DCM), a disease characterized by an enlarged and weak heart muscle that cant efficiently pump blood.

An international, multi-centre study led by Dr. James White, MD, a clinician and researcher at the University of Calgarys Cumming School of Medicine (CSM), has revealed magnetic resonance imaging (MRI) can be used to predict major cardiac events for people diagnosed with DCM.

Whites study, published in Circulation Cardiovascular Imaging, confirms about 40 per cent of patients with DCM have scarring patterns on their heart muscle which can be seen with MRI. These patterns are associated with higher risk of future heart failure admissions, life-threatening heart rhythms and death.

The study, which was the largest ever conducted using MRI in patients with DCM, also shows that cardiac MRI can play an important role in guiding the care of individual patients with heart failure, an approach called personalized medicine. The results of this study could lead to trials looking at how patients at higher risk may benefit from more intensive treatments. White says that treating patients with DCM is challenging because there is a lack of understanding into what causes the disease and why patients respond differently to the available treatments.

We have tended to think of dilated cardiomyopathy as one type of heart disease and that all patients should respond the same way, but we are learning that it is a collection of disease states that affect each patient differently, says White, explaining those that dont respond well to treatments are more prone to cardiac arrest, which kills about 35,000 Canadians annually.

The purpose of our study was to see if we could find individual patient features that can help us prescribe life-saving therapies, such as the ICD (implantable cardioverter defibrillator).

White and his team assembled the MINICOR (Multimodal International Cardiovascular Outcomes Registry) group, which involves 12 centres from Canada, the United States, Spain and Italy, to provide researchers access to highly standardized data collected from patients around the world with the goal of promoting personalized care for patients with cardiovascular disease.

We can have a much greater impact on patient care and on clinical practice in general when we work together, says White The true benefit of initiatives like this is our ability to test innovative ideas quickly and show they can work in different health-care systems and patient populations. This is the unique power of multi-national collaborations.

White and his team of data scientists and students are currently tracking the health of more than 10,000 Albertans who have undergone cardiac MRI.With this data they are developing new approaches to deliver personalized risk prediction models for patients with cardiovascular disease.

Libin Institute director Dr. Paul Fedak, MD, PhD, is excited about the potential of this project and its alignment with the institutes aim to lead in the area of precision cardiovascular medicine.

These are important steps towards personalizing care decisions for individual patients, says Fedak. We are constantly being reminded that the more we know about each patient and their own disease, the better we can make decisions to improve their health.

James Whiteis a professor in the departments of Cardiac Sciences, Radiology and Medicine and a member of the Libin Cardiovascular Institute at the Cumming School of Medicine.

James White led an international study on heart failure. Here, he stands in front of the cardiac MRI machine in the Stephenson Cardiac Imaging Centre.

Britton Ledingham for Libin Cardiovascular Institute

Read the rest here:
Researcher leads international study of patients at risk of heart failure and death - UCalgary News

Read More...

Companion Diagnostics Market Insights on Scope the COVID-19 – 3rd Watch News

Saturday, July 11th, 2020

Global Companion Diagnostics Market was valued US$ 2.68 Bn in 2017 and is expected to reach US$ 10.76 Bn by 2026, at a CAGR of 18.98 % during a forecast period.

A diagnostic is a process of determining disease, condition, and illness, which clarifies a person symptoms & signs that is useful for an individuals treatment. Companion diagnostic is a medical device that provides important information required for the safety & effective use of a biological product. Companion diagnostics are majorly used in the oncology area due to the growing incidence of cancer and it improvers the focus on cancer research.

The important driving factors of the global companion diagnostics market are the rising demand for targeted therapy and the increasing prevalence of cancer. Rising awareness of personalized medicines, growing cases of adverse drug reactions, and co-development of drug & diagnostic technology is also boosting the growth market.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/5712

Increasing demand for next-generation sequencing and emerging applications of companion diagnostics in oncology indication provides key opportunities for companion diagnostics market. However, high cost involved in the development of therapeutics & diagnostic tests, and issues related to intellectual property rights is limiting the market growth.

The assay kits & reagents segment accounted for the largest share in the market, owing to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH. Polymerase chain reaction (PCR) is a method widely used in molecular biology to make many copies of a specific DNA segment and is occupied the largest share during the forecast period.

Next-generation sequencing (NGS) is the technology that is used to arrange millions of small fragments of DNA in a line at the same time NGS are capable of processing multiple DNA sequences in parallel. NGS is expected to grow at a high CAGR during the forecast period owing to the availability of next-generation sequencing at low cost, technological advancements and high prevalence of cancer cases.

The supportive government initiatives to promote precision medicine research, along with the strategic alliances between key market players for companion diagnostics test development is expected to hold the largest share in North America followed by Europe throughout the forecast period. Increasing technological advancements aimed at developing companion diagnostic tests for new indications such as neurology, infectious diseases are also expected to hold the largest share in this region. Europe is rising demand for efficiency in healthcare & strengthening healthcare system and Germany is the largest market in Europe due to the presence of major market players and growing demand for technological advancement in these regions. However, Middle East & Africa are estimated to have a limited but stable growth owing to low healthcare expenditure and demand for primary healthcare services in this region.

Key player operating in the global companion diagnostics market are Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, BioMrieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe Technologies, Inc., MolecularMD Corporation, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., ArcherDx, Inc., Exosome Diagnostics, Inc., NeoGenomics, Inc., MDxHealth, Inc., and NanoString Technologies, Inc.

Scope of Global Companion Diagnostics Market:

Global Companion Diagnostics Market, by Product and Service:

Assay kits & reagents

Software & service

Global Companion Diagnostics Market, by Technology:

In situ hybridization

Polymerase chain reaction

Immunohistochemistry

Next-generation sequencing

Other technologies

Global Companion Diagnostics Market, by Indications:

Oncology

Neurology

Infectious diseases

Other indications

Global Companion Diagnostics Market, by End-User:

Pharmaceutical & biopharmaceutical companies

Reference laboratories

Other end users

Global Companion Diagnostics Market, by Region:

North America

Europe

Asia-Pacific

South America

Middle East & Africa

Key Player Operating In the Global Companion Diagnostics Market:

Abbott Laboratories

Agilent Technologies, Inc.

ARUP Laboratories

BioMrieux SA

Danaher Corporation

F. Hoffmann-La Roche AG

Illumina, Inc.

Invivoscribe Technologies, Inc.

MolecularMD Corporation

Myriad Genetics, Inc.

QIAGEN N.V.

Thermo Fisher Scientific Inc.

ArcherDx, Inc.

Exosome Diagnostics, Inc.

NeoGenomics, Inc.

MDxHealth, Inc.

NanoString Technologies, Inc.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/5712

Read more from the original source:
Companion Diagnostics Market Insights on Scope the COVID-19 - 3rd Watch News

Read More...

Got $5,000? Buy Stocks in These 5 Industries Now – Motley Fool

Saturday, July 11th, 2020

This year has truly been a tale of two markets. For a five-week period in the first quarter, downside momentum in the stock market tied to the coronavirus disease 2019 (COVID-19) pandemic was unlike anything we'd ever seen before. But over the past 3.5 months, Wall Street has undertaken its strongest rally in more than two decades.

If 2020 has taught investors anything, it's the power of long-term investing and sticking with your initial investment thesis, even if some pretty big hiccups present themselves.

It's also taught investors that you don't need to be rich to become rich in the stock market. If you have $5,000 in cash at your disposal that won't be needed to pay bills or for emergencies, then you have more than enough capital to put to work in some of the fastest-growing industries in the new bull market. Here are five industries you'd be smart to consider buying into right now with $5,000.

Image source: Getty Images.

If these industries were being presented in any particular order (which they aren't), cloud computing would likely be at the top of the list. Even before COVID-19 became a serious concern, we were already witnessing a steady transition toward remote and shared-work capabilities. COVID-19 simply provided a shot in the arm to facilitate this transformation even faster. In my mind, there's little question that cloud growth should consistently remain in the double-digits on an annual basis throughout this decade.

While there are no shortage of cloud service companies to choose from, e-commerce giant Amazon (NASDAQ:AMZN) might be the preferred stock to own. Amazon Web Services (AWS) operates as an infrastructure-as-a-service player, which is a fancy way of saying that it supplies small and medium-sized businesses with the tools necessary to form the building blocks of their cloud-based platform. In just a five-quarter stretch, AWS has grown from 11% of Amazon's total sales to 13.5% of total sales, while accounting for the lion's share of its operating income during the first quarter.

Make no mistake about it, high-margin cloud sales are going to generate insane amounts of cash flow for Amazon and other cloud-service providers.

Image source: Getty Images.

If there's such a thing as a no-brainer industry to buy, it's cybersecurity. No matter how well or poorly the U.S. and global economy are performing, hackers don't take time off. This makes the hardware and subscription protection services provided by cybersecurity companies an absolute necessity. And with more businesses pushing into the cloud than ever before, there's a growing need for more sophisticated security solutions.

Here, I continue to be a fan of what Palo Alto Networks (NYSE:PANW) is doing. In recent quarters, Palo Alto has deemphasized physical firewall products in favor of higher-margin subscription and support services. This will lead to more consistent revenue recognition and should help reduce what little client churn the company is contending with. And yes, it'll help improve operating margins over the long run, too.

Palo Alto has also diversified its product offerings through numerous bolt-on acquisitions. Look for the company to continue spending aggressively on innovation and inorganic growth to improve its cloud-protection market share.

Image source: Getty Images.

The cannabis industry gets a bit of a bad rap given that the bubble finally burst in pot stocks over the past 15 months. Supply issues to our north, high tax rates in select U.S. markets, and financing concerns throughout North America have coerced caution from investors.

But this is still an industry where tens of billions of dollars in sales are conducted annually in the black market. It's expected that these illicit channels will gradually give way to legal sales over time and offer the North American marijuana industry a double-digit growth opportunity throughout much of the 2020s.

An intriguing name to consider here is Green Thumb Industries (OTC:GTBI.F). Green Thumb is a multistate operator with 48 open dispensaries and licenses to open as many as 96 stores in a dozen states. Green Thumb is currently generating about two-thirds of its revenue from higher-margin derivatives, rather than dried cannabis flower, which is a big reason it looks to be on the cusp of recurring profitability.

Furthermore, Green Thumb has established a significant presence in Illinois, which opened its doors to recreational weed sales on Jan. 1, 2020, as well as Nevada, which has the potential to lead the nation in cannabis spending per-capita by mid-decade.

Image source: Getty Images.

Another industry that looks set to come into its own is the Internet of Things (IoT). By IoT, I'm talking about wireless devices that can communicate with other wireless devices, as well as data centers. Like marijuana, IoT was hyped up too quickly in the 2010s, but has now had time to mature. This growing focus on technology making our lives easier is bound to have a positive impact on IoT companies for years to come.

The name to watch here is NXP Semiconductors (NASDAQ:NXPI), which generated almost half of its revenue last year from the automotive industry, with industrial equipment, communications, and mobile comprising the remainder of sales in 2019. In particular, NXP is a leader in self-driving and sensor equipment used in a number of newer automobiles. Between 2018 and 2021, NXP expects to have delivered a compound annual growth rate of 7% to 10% (this includes 2021 as an estimate), which is outpacing the CAGR for the IoT auto market of 5% to 7% over this same time frame.

Additionally, don't overlook other growth drivers for NXP, such as mobile payment adoption, the rollout of 5G networks, and its scalability in industrial processing applications.

Image source: Getty Images.

Last, but not least, don't forget about the personalized medicine push. Anything that caters to individual patient needs, especially during a pandemic, is likely to see demand improve significantly over the long run.

As a perfect example, take a closer look at Teladoc Health (NYSE:TDOC), which provides telemedicine visits for patients. Not only are these virtual visits critical during the pandemic to ensure that sick people remain in their homes, but it's a considerably more convenient method of arranging a consultation with a physician. It also doesn't hurt that telemedicine visits tend to be cheaper for insurance providers.

During the pandemic-impacted first quarter, Teladoc reported an absurd 92% uptick in virtual visits, with its paying membership increasing by 61% to 43 million people in the United States. Visit-fee-only access increased by a whopping 89%, as well. Though there's little question that Teladoc Health will continue to lose money in the near-term as it enhances its platform and makes complementary acquisitions, it clearly has the tools necessary to become a major player in personalized health over the next decade.

See the article here:
Got $5,000? Buy Stocks in These 5 Industries Now - Motley Fool

Read More...

Page 19«..10..18192021..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick